06/23/22 9:00 AMNasdaq : KTTA acquisitionlow floatInvestor Group Comments on Pasithea Therapeutics’ Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC, who together are the largest stockholder of Pasithea Therapeutics Corp., today issued the following statement regarding the Company's dilutive and reactionary acquisition of Alpha-5 integrin, LLC:. Pasithea has already been suffering from significant corporate...RHEA-AInegative
06/23/22 8:00 AMNasdaq : KTTA, KTTAW conferenceslow floatPasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and BeyondPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced that itsRHEA-AIneutral
06/22/22 8:00 AMNasdaq : KTTA, KTTAW acquisitionlow floatPasithea Therapeutics Acquires Alpha-5 Integrin, LLC- Alpha-5 is a potentially first-in-class monoclonal antibody for the treatment of amyotrophic lateral sclerosis (ALS) and other neurological diseases - - Expands pipeline across Pasithea's core therapeutic areas to drive enhanced growth - - Closing consideration of 3.26 million shares of PasitheaRHEA-AIpositive
04/14/22 4:15 PMNasdaq : KTTA, KTTAW conferenceslow floatPasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced its ChiefRHEA-AIneutral
03/30/22 4:15 PMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022MIAMI BEACH,RHEA-AIvery positive
03/08/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Collaboration with The Glimpse GroupPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” orRHEA-AIpositive
02/24/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022MIAMI BEACH, Fla., Feb.RHEA-AIvery positive
02/09/22 8:00 AMNasdaq : KTTA, KTTAW managementlow floatPasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel WeinbergerPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research andRHEA-AIneutral
02/03/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research andRHEA-AIneutral
01/26/22 8:00 AMNasdaq : KTTA, KTTAW low floatPasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine TreatmentsPasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novelRHEA-AIneutral